Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Science Times Observer.
Press releases published on May 8, 2025

Lantronix Reports Results for Third Quarter of Fiscal 2025
Third Quarter Net Revenue of $28.5 Million Third Quarter GAAP EPS of ($0.10) Third Quarter Non-GAAP EPS of $0.03 IRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Lantronix Inc. (NASDAQ: LTRX), a global leader of compute and connectivity for the Internet of …

TELA Bio Reports First Quarter 2025 Financial Results
MALVERN, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended …

CEA Industries Inc. Provides Update on Fat Panda Acquisition
Transaction reflects CEA Industries’ strategic evolution and pivotal entry into attractive high-growth vape market Accelerates Fat Panda’s growth initiatives as central Canada’s largest retailer and manufacturer of e-cigarettes, vape devices and e-liquids …

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update
- Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) - - Expanded intellectual property portfolio with second patent covering …

Synaptics Reports Third Quarter Fiscal 2025 Results
Quarterly revenues increased 12% year-over-year, driven by a 43% growth in Core IoT product sales Q3’25 Financial Results Revenue of $266.6 million GAAP gross margin of 43.4% Non-GAAP gross margin of 53.5% GAAP loss per share of $0.56 Non-GAAP diluted …

Snail, Inc. Sets First Quarter 2025 Conference Call for Wednesday, May 14, 2025 at 4:30 p.m. ET
CULVER CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, will hold a conference call and webcast on …

Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2025
FRAMINGHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended March …

SIGA Reports Financial Results for Three Months Ended March 31, 2025
Received $26 Million IV TPOXX Procurement Order from the U.S. Government in March $94 million in TPOXX Orders (to be Delivered to U.S. Strategic National Stockpile) outstanding as of March 31, 2025 Corporate Update Conference Call Today at 4:30 PM ET NEW …

Inseego Reports First Quarter 2025 Financial Results
Q1 2025 revenue of $31.7 million Q1 2025 positive Adjusted EBITDA of $3.7 million and GAAP Net Loss of $1.6 million Ninth consecutive quarter of positive Adjusted EBITDA SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Inseego Corp. (Nasdaq: INSG) (the “Company …

Aqua Metals Expands Product Platform with Advancements in Nickel, MHP, and LFP Recycling; Reports First Quarter 2025 Results
RENO, Nev., May 08, 2025 (GLOBE NEWSWIRE) -- Aqua Metals (NASDAQ: AQMS), an innovator in domestic critical minerals refining, AquaRefining™, today reported financial results for the first quarter ended March 31, 2025, and highlighted major technology and …

Soleno Therapeutics Announces Oral Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ESPE and ESE 2025
REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will present data from its …

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
Activities supporting the close out of BEACON-IPF continue; topline data expected in the second quarter of 2025 Recently announced strategic realignment of workforce and operations will extend cash runway to support execution of late-stage clinical trials …

NurExone Advances Vision Restoration Strategy with Preclinical Data Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025
TORONTO and HAIFA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system …

PDF Solutions® Announces First Quarter 2025 Financial Results
SANTA CLARA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PDF Solutions, Inc. (Nasdaq: PDFS), a leading provider of comprehensive data solutions for the semiconductor and electronics ecosystem, today announced financial results for its first quarter ended …

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results
Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Phase 3 registrational clinical trial of …

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025
1Q25 Total Product Revenue of $49.3M FY25 Total Product Revenue Guidance Revised to $250M-$300M FY25 Operating Expenses Reduced and 2H26 Cash Runway Guidance Maintained 2025 Regulatory Approvals for Amtagvi® Expected in the UK, EU, and Canada On Track to …

Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial
GAITHERSBURG, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer …

Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress
– Generated Q1’25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed …

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress
Topline data from multiple Phase 2 studies expected throughout 2025 • Q2 readout from VTX3232 study in patients with early Parkinson’s disease • H2 readout from VTX2735 study in patients with recurrent pericarditis • H2 readout from VTX3232 study in …

Research Frontiers Reports First Quarter 2025 Financial Results and Will Host a Conference Call at 4:30p.m. Today
WOODBURY, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq: REFR) announced its financial results for its first quarter of 2025. Management will host a conference call today at 4:30 p.m. Eastern Time to discuss its financial and …